Yasmeen Rahimi Analyst Performance

Managing Director, Senior Research Analyst in Biotechnology at Piper Sandler

Yasmeen Rahimi is a stock analyst at Piper Sandler in the medical sector, covering 20 publicly traded companies. Over the past year, Yasmeen Rahimi has issued 15 stock ratings, including buy and hold recommendations. While full access to Yasmeen Rahimi's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Yasmeen Rahimi's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 29 Last 7 Years
Buy Recommendations: 93.10% 27 Buy Ratings
Companies Covered: 20 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	93.1%	27 ratings
Hold	6.9%	2 ratings
Sell	0.0%	0 ratings

Out of 29 total stock ratings issued by Yasmeen Rahimi at Piper Sandler, the majority (93.1%) have been Buy recommendations, followed by 6.9% Hold.

Best & Worst Calls

Best Call
0000.0%
MDGL
Nov 2017
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
OHRP
Nov 2017
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	20 companies

Yasmeen Rahimi, an analyst at Piper Sandler, currently covers 20 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 20 companies	100.0%

Yasmeen Rahimi of Piper Sandler specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 11 companies	55.0%
MED - DRUGS 5 companies	25.0%
PHARMACEUTICAL PREPARATIONS 4 companies	20.0%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
TRML Tourmaline Bio	9/11/2025	Downgrade	$47.60	$48.00	Neutral
TENX Tenax Therapeutics	9/8/2025	Initiated Coverage	$5.99	$20.00	Overweight
PRTA Prothena	8/28/2025	Lower Price Target	$8.41	$15.00	Overweight
IVA Inventiva	8/27/2025	Initiated Coverage	$4.59	$26.00	Overweight
IVA Inventiva	8/27/2025	Initiated Coverage	$6.35	$26.00	Overweight
PLRX Pliant Therapeutics	8/8/2025	Lower Price Target	$1.68	$4.00	Overweight
VRNA Verona Pharma PLC American Depositary Share	6/23/2025	Set Price Target	$95.62	$160.00	Overweight
TVRD Tvardi Therapeutics	6/12/2025	Initiated Coverage	$26.22	$78.00	Overweight
PRTA Prothena	5/27/2025	Lower Price Target	$4.53	$81.00	Overweight
SLNO Soleno Therapeutics	4/24/2025	Boost Price Target	$71.73	$145.00	Overweight
EWTX Edgewise Therapeutics	4/2/2025	Reiterated Rating	$15.98	$51.00	Overweight
LXRX Lexicon Pharmaceuticals	3/7/2025	Lower Price Target	$0.39	$6.00	Overweight
AVTX Avalo Therapeutics	2/28/2025	Initiated Coverage	$6.60	$48.00	Overweight
PRTA Prothena	2/26/2025	Boost Price Target	$14.46	$110.00	Overweight
DRUG Bright Minds Biosciences	1/23/2025	Initiated Coverage	$33.35	$93.00	Overweight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.